Posted by Michael Wonder on 06 Sep 2020
NICE not supportive of encorafenib for metastatic colorectal cancer
4 September 2020 - NICE has responded to the request of the Department of Health and Social Care to produce guidance on the use encorafenib in combination with cetuximab in the NHS in England.
Encorafenib plus cetuximab is not recommended, within its marketing authorisation, for treating BRAF V600E mutation positive metastatic colorectal cancer in adults who have had previous systemic treatment.
The treatment of patients with BRAF V600E mutation-positive metastatic colorectal cancer after previous systemic treatment includes combination chemotherapy, usually FOLFIRI (5‐fluorouracil, folinic acid and irinotecan) followed by trifluridine–tipiracil then best supportive care. Encorafenib plus cetuximab is the first colorectal cancer treatment that targets the BRAF V600E mutation, and could be used as second or third-line treatment.
Clinical trial evidence shows that encorafenib plus cetuximab increases how long people live compared with FOLFIRI plus cetuximab or irinotecan plus cetuximab. However, these drug combinations are not used in NHS clinical practice
